Heart scans reveal how fabry drug calms inflammation
NCT ID NCT07235709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study watches 25 people with Fabry disease to see how the drug agalsidase alfa changes heart inflammation over one year. Participants get special heart scans (PET-CMR) at the start and after 12 months of treatment. The goal is to learn if the drug reduces inflammation in the heart muscle.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
RECRUITINGSeoul, 03722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early enzyme therapy save kidneys in fabry disease?
- Can continued lucerastat access help fabry patients?
- Can a single gene infusion rewrite the story of fabry disease?
- Fabry disease sperm study halted early
- Heart study reveals hidden link between blood vessels and muscle blockage
- Taiwan study sheds light on rare fabry mutation and treatment effects